Adicet Bio (ACET) to Release Earnings on Tuesday

Adicet Bio (NASDAQ:ACET - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Adicet Bio to post earnings of ($0.34) per share for the quarter.

Adicet Bio (NASDAQ:ACET - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Stock Down 4.0 %

NASDAQ ACET traded down $0.03 during trading hours on Tuesday, hitting $0.64. The company had a trading volume of 24,943 shares, compared to its average volume of 737,515. The firm has a market cap of $52.85 million, a P/E ratio of -0.37 and a beta of 1.76. The business has a fifty day simple moving average of $0.70 and a 200-day simple moving average of $0.92. Adicet Bio has a fifty-two week low of $0.45 and a fifty-two week high of $1.87.

Analyst Ratings Changes

Several research analysts have issued reports on ACET shares. StockNews.com upgraded shares of Adicet Bio from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. JMP Securities reiterated a "market perform" rating on shares of Adicet Bio in a report on Thursday, February 6th. HC Wainwright reissued a "neutral" rating on shares of Adicet Bio in a research note on Friday, March 7th. Finally, Guggenheim reissued a "buy" rating and set a $7.00 target price on shares of Adicet Bio in a research report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.